Clinically significant medical history or condition which precludes participation

Clinically significant ECG abnormality

Clinically significant VS or PE abnormality

Clinically significant screening lab abnormality

Abnormal lung function (FEV1 \<80% predicted)

Respiratory infection within 14 days of randomization

HBV, HCV, or HIV

Breastfeeding or pregnant female

History of alcohol abuse or illicit drug use within past 24 months

Use of any tobacco or nicotine-containing product within past 6 months

Use of any herbal supplement, over-the-counter drug, or prescription drug that is not allowed per protocol

Use of any investigational drug within past 30 days

Use of any investigational monoclonal antibody or recombinant protein within past 90 days

Donation of plasma within past 7 days

Donation or loss of whole blood within past 56 days

* Simplified list of I/E criteria; unabridged list available upon request.

A Phase 1 Study of AIR645 in Healthy Subjects and Subjects With Controlled Asthma